Engineering a new type of immune therapy using three different cell types
Combinatorial engineering of a three-cell synthetic immunotherapy system
['FUNDING_R21'] · STANFORD UNIVERSITY · NIH-11120022
This study is exploring a new way to treat cancer and autoimmune diseases by making special immune cells work together better, so if you're looking for innovative treatments, this research might be for you!
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-11120022 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to cancer and autoimmune disease treatment by engineering T cells, natural killer (NK) cells, and macrophages to work together as a synthetic immune system. Unlike current therapies that use these immune cells in isolation, this project aims to combine them to enhance their effectiveness against diseases. The researchers will create and test various combinations of these engineered cells to identify the most effective configurations for targeting cancer and other conditions. By modulating the signaling pathways of these cells, they hope to improve their ability to coordinate immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with cancers or autoimmune diseases who may benefit from advanced immunotherapy options.
Not a fit: Patients with conditions unrelated to cancer or autoimmune diseases may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for cancer and autoimmune diseases by harnessing the power of a coordinated immune response.
How similar studies have performed: Previous research has shown promise in using engineered immune cells for therapy, but this approach of combining multiple cell types is relatively novel.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DANIELS, KYLE GABRIEL — STANFORD UNIVERSITY
- Study coordinator: DANIELS, KYLE GABRIEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy, Autoimmune Diseases, autoimmune disorder, autoimmunity disease, cancer antigens